Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma
- PMID: 40782703
- DOI: 10.1016/j.lungcan.2025.108679
Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma
Abstract
Pleural mesothelioma (PM) is a rare and lethal cancer with limited treatment options. Intratumor heterogeneity (ITH) has been postulated as one of the reasons for the poor treatment response observed in most PM patients. In this regard, we aimed to characterize ITH in a multi-site tumor specimen using single-cell RNA-sequencing (scRNA-seq).
Methods: Tumor cells from three distant biopsies (costal, diaphragmatic, and mediastinal) of an epithelioid PM were analyzed with scRNA-seq.
Results: Three main cell states were identified in all regions: C1, stem-like; C2, epithelial-like; and C3, mesenchymal-like. C1 state was the most prominent globally, although it was less abundant in the mediastinal biopsy, compared to the other two studied regions. Trajectory analysis was suggestive of an epithelial-mesenchymal plasticity dynamic, including a stem-like intermediate state. Signatures of upregulated genes in each state (SigC1, SigC2, SigC3) were obtained and assessed in a large cohort of PM samples. Patients with tumors enriched in SigC3 were associated with worse survival and with reduced sensitivity to standard of care PM regimens. Additionally, SigC1 appeared to be potentially more sensitive to anti-angiogenic therapies.
Conclusions: This study highlights that scRNA-seq is useful to capture PM cellular and molecular heterogeneity and identifies gene-expression signatures with potential clinical relevance for future treatment tailoring.
Keywords: Pleural mesothelioma; epithelial-mesenchymal plasticity; epithelial-to-mesenchymal transition; gene expression signature; single-cell RNA-sequencing, tumor heterogeneity.
Copyright © 2025 Elsevier B.V. All rights reserved.
Conflict of interest statement
Declaration of competing interest IM reports honoraria for lectures from Merck Sharp Dohme. SP reports consultancy or advisory fees from AstraZeneca and Roche. RP received honoraria, consulting fees, or participation in advisory boards from AstraZeneca, Guardant Health, Pfizer; and support for travel from MSD. HH is co-founder and Chief Scientific Officer of Omniscope, a Scientific Advisory Board member at Nanostring and Mirxes, a consultant for Moderna and Singularity, and has received honoraria from Genentech. EN received research funding from Roche, Pfizer, Merck-Serono and Bristol Myers Squibb (BMS), participated in advisory boards or received honoraria from Amgen, Apollomics, AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, Daiichi-Sankyo, Genmab, Illumina, Johnson & Johnson, Lilly, Merck Sharp & Dohme (MSD), Merck-Serono, Pfizer, Pierre Fabre, Qiagen, Regeneron, Roche, Sanofi and Takeda, and received travel support from Roche, Takeda, Janssen, and MSD. XS participated in lectures from Roche. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
